Company & Industry News
Cannabiz Consumer Group’s (C2G) recently released survey, CannaUse™ provides insights into legal medicinal cannabis consumers. Cost is Key C2G’s CannaUse™ study examined medicinal cannabis use among more than 55,000 respondents. Findings conclude that one of the major considerations in using cannabis for medicinal purposes is not just the level of relief it may provide but … Continue reading "Costs, Co-pays and Cannabis"
Sharing cannabis stories One of the most interesting aspects of launching C2G is that every meeting begins with someone’s cannabis story – a sort of confessional that we don’t seek but is instead volunteered. Everyone knows someone who is using cannabis for managing pain or another medical need, if not doing so themselves. If we … Continue reading "Shattering Cannabis Stigma and Stereotypes: Mary Jane Comes Out of the Shadows"
Candidates and voters take note. From the growth of the economy to the de-institutionalization of our prison system, the issue of cannabis legalization is far reaching, whether or not someone is a potential consumer. Currently, data from C2G’s 2015 CannaUse study shows that approximately 52% of the adult population over age 21 have used cannabis in … Continue reading "Cannabis Legalization not far behind abortion and climate change as a key 2016 election issue"
Chief Product Officer Rich Maturo, and Chief Executive Officer Leslie Townsend featured in this month’s Online MR magazine. Leslie Townsend talks about why the marijuana industry needs its own market research company in her interview. “It is going to be a very disruptive industry, impacting everything from agricultural land use to prison reform.” Rich Maturo … Continue reading "Online MR Double Feature: Metrics for a New Industry & How Marijuana Changes Travel & Tourism"
Since we launched C2G, several momentous events have occurred in the industry as we enter the election cycle. First and foremost, the DEA released a long-awaited decision whether or not it would reclassify marijuana (MJ) from a Schedule 1 narcotic, meaning they consider it as dangerous as heroin and more dangerous than the Schedule 2 … Continue reading "DEA Takes Baby Steps, but Cannabis Industry is Ready to Walk."